ETON
Eton Pharmaceuticals Inc
NASDAQ: ETON · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$55.62
+0.47% today
Updated 2026-10-05
Market cap
$1.65B
P/E ratio
147.90
P/S ratio
15.61x
EPS (TTM)
$0.39
Dividend yield
—
52W range
$14 – $66
Volume
0.6M
WallStSmart proprietary scores
52
out of 100
Grade: C
Hold
Investment rating
7.3
Growth
B+5.0
Quality
C+6.5
Profitability
B4.0
Valuation
C4/9
Piotroski F-Score
Moderate
-0.3
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →271 stocks currently score above 75
Price targets
Analyst target
$71.00
+27.65%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $7.25M — positive
+ Revenue growth 98.60% QoQ
Risks
- Altman Z -0.31 — distress zone
- P/E 147.90x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $21.25M | $31.64M | $39.01M | $79.95M | $105.59M |
| Net income | $-9.02M | $-936000.00 | $-3.82M | $-4.60M | $11.58M |
| EPS | — | — | — | — | $0.39 |
| Free cash flow | $2.03M | $6.04M | $943000.00 | $10.19M | $7.25M |
| Profit margin | -42.45% | -2.96% | -9.80% | -5.75% | 12.00% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-17 | ADAMS, JENNIFER MCKIE | Sale | 50,000 | — |
| 2026-06-17 | ADAMS, JENNIFER MCKIE | Buy | 50,000 | $3.78 |
| 2026-05-28 | BRYNJELSEN, SEAN | Sale | 119,852 | $31.88 |
Peer comparison
Smart narrative
Eton Pharmaceuticals Inc trades at $55.62. representing a P/E of 147.90x trailing earnings. Our Smart Value Score of 52/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -0.31, it sits in the distress. TTM revenue stands at $105.59M. with profit margins at 12.00%.
Frequently asked questions
What is Eton Pharmaceuticals Inc's stock price?
Eton Pharmaceuticals Inc (ETON) trades at $55.62, on a P/E of 147.9x and a P/S of 15.6x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Eton Pharmaceuticals Inc overvalued?
Eton Pharmaceuticals Inc carries a Smart Value Score of 52/100 (Grade C), which we rate Hold. That score blends growth, quality, and valuation into one read.
What is the price target of Eton Pharmaceuticals Inc (ETON)?
The 12-month analyst consensus target is $71.00, about 27.7% above the current $55.62. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Eton Pharmaceuticals Inc's revenue?
Eton Pharmaceuticals Inc's trailing twelve-month revenue is $105.59M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Eton Pharmaceuticals Inc's Altman Z-Score is -0.31, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio15.61x
ROE-4.82%
Beta0.90
50D MA$52.94
200D MA$30.93
Shares out0.03B
Float0.02B
Short ratio—
Avg volume0.6M
Performance
1 week+6.60%
1 month+17.24%
3 months+44.65%
YTD+111.12%
1 year—
3 years—
5 years—